Drug Combo Shows Benefits in Fit Patients With Acute Myeloid Leukemia

By News Health
45 minutes Ago

(MedPage Today) — ORLANDO — Azacitidine and venetoclax (Venclexta) significantly improved event-free survival (EFS) in newly diagnosed fit adults with acute myeloid leukemia (AML) compared with conventional induction chemotherapy, a phase II…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118890

Author :

Publish date : 2025-12-08 18:49:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Many Patients Still Face GP Referral ‘Black Hole’

Adding Procedures, Cutting the Paperwork

CDC Panel Targets Size of Childhood Vaccine Schedule, Safety of Aluminum Adjuvants

Experts Evaluate Aging and Hematologic Disease at ASH

Private Care Rise Sparks Warning for NHS Scotland’s Future

IV Iron Tied to Lower Mortality Risk in Anemics Battling Infection